Lisata Therapeutics Inc LSTA
News
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - LFCR, LSTA, FSHP and BWIN - IS IT A FAIR DEAL FOR YOU?
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry — LSTA, FSHP, BWIN, and ACVA
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

